| 0 (0%) | 11-11 19:27 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.79 | 1-year : | 6.48 |
| Resists | First : | 4.95 | Second : | 5.55 |
| Pivot price | 4.48  |
|||
| Supports | First : | 4 | Second : | 3.32 |
| MAs | MA(5) : | 4.24 |
MA(20) : | 4.64 |
| MA(100) : | 3.91 |
MA(250) : | 4.23 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 23.2 |
D(3) : | 18.3 |
| RSI | RSI(14): 42 | |||
| 52-week | High : | 7.44 | Low : | 2.65 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VYGR ] has closed above bottom band by 24.3%. Bollinger Bands are 0.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.4 - 4.42 | 4.42 - 4.44 |
| Low: | 3.98 - 4 | 4 - 4.02 |
| Close: | 4.22 - 4.26 | 4.26 - 4.3 |
Tue, 11 Nov 2025
Will VYGR stock benefit from AI adoption - Entry Point & AI Driven Stock Reports - newser.com
Mon, 10 Nov 2025
Voyager Therapeutics: Q3 Earnings Snapshot - CTPost
Mon, 10 Nov 2025
Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Mon, 10 Nov 2025
Voyager (VYGR) Projects Strong Financial Position Through 2028 - GuruFocus
Mon, 10 Nov 2025
Voyager Therapeutics (VYGR) Partners with Transition Bio for ALS and FTD Drug Discovery - GuruFocus
Mon, 10 Nov 2025
Voyager (VYGR) Posts Strong Q3 Revenue, Announces Strategic Coll - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 55 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 16.1 (%) |
| Held by Institutions | 59.8 (%) |
| Shares Short | 3,220 (K) |
| Shares Short P.Month | 3,140 (K) |
| EPS | -1.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.4 |
| Profit Margin | -253.5 % |
| Operating Margin | -704.4 % |
| Return on Assets (ttm) | -20.3 % |
| Return on Equity (ttm) | -37.3 % |
| Qtrly Rev. Growth | -82.5 % |
| Gross Profit (p.s.) | -1.55 |
| Sales Per Share | 0.76 |
| EBITDA (p.s.) | -2.15 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -114 (M) |
| Levered Free Cash Flow | -61 (M) |
| PE Ratio | -2.3 |
| PEG Ratio | 0 |
| Price to Book value | 0.96 |
| Price to Sales | 5.54 |
| Price to Cash Flow | -2.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|